Valuation: Epigenomics AG

Market Cap 789K 909K 736K 676K 1.28M 86.47M 1.29M 8.68M 3.39M 43.22M 3.41M 3.34M 143M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.76M 13.54M 10.96M 10.07M 19.04M 1.29B 19.25M 129M 50.52M 644M 50.84M 49.73M 2.13B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
1 day-1.10%
1 week-5.26%
Current month-4.26%
1 month-35.71%
3 months-3.23%
6 months+3.21%
1 week 0.9
Extreme 0.9
0.94
1 month 0.87
Extreme 0.87
1.29
Current year 0.84
Extreme 0.84
1.55
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
3.65
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 2024-01-31
Director TitleAgeSince
Chairman 58 2023-02-28
Director/Board Member 55 2020-05-31
Director/Board Member 56 2024-02-04
Date Insider Type Main position Quantity % Market Cap.
12/29/22 Buy

Chief Financial Officer

2,000 0.0122%
9/7/21 Sell

Director

7,790 0.0637%
2/1/21 Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
+1.11%-5.26%+1.12%-69.75% 909K
+6.23%+9.01%+125.02%+259.44% 3.9B
+3.48%-16.60%+90.83%+81.64% 3.73B
-1.59%+31.72%+273.73%+324.23% 2.44B
+2.61%+5.38%-27.47%-35.38% 2.22B
+1.04%-7.23%+54.06%-39.78% 1.95B
+0.16%-6.27%+183.26%-44.09% 948M
+4.68%+6.68%-4.28%+10.47% 892M
-0.46%+3.70%-38.25%-11.10% 517M
+8.68%+9.39%+1.08% - 506M
Average +2.37%+4.46%+65.91%+52.86% 1.71B
Weighted average by Cap. +2.91%+3.61%+98.78%+115.31%

Financials

2024 2025
Net sales - 24K 27.64K 22.38K 20.56K 38.88K 2.63M 39.3K 264K 103K 1.31M 104K 102K 4.35M
Net income -3.35M -3.86M -3.13M -2.87M -5.43M -367M -5.49M -36.85M -14.4M -184M -14.5M -14.18M -608M -314K -362K -293K -269K -509K -34.4M -514K -3.45M -1.35M -17.2M -1.36M -1.33M -56.98M
Net Debt 10.46M 12.04M 9.75M 8.95M 16.94M 1.15B 17.12M 115M 44.93M 573M 45.22M 44.23M 1.9B 10.97M 12.63M 10.23M 9.39M 17.77M 1.2B 17.96M 121M 47.13M 601M 47.43M 46.39M 1.99B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
3
Date Price Change Volume
26-08-05 0.9100 +1.11% 0
26-08-04 €0.9000 -1.10% 0
26-08-03 €0.9100 -3.19% 2
26-07-31 €0.9400 -0.53% 97
26-07-30 €0.9450 +0.53% 33

Annual profits - Rate of surprise